Adverse event due to a likely interaction between sodium aescinate and ginkgo biloba extract: a case report. (1st February 2017)

• Record Type: Journal Article
• Authors: Ji, H.; Zhang, G.; Yue, F.; Zhou, X.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 42:Number 2(2017)
• Page Start: 237
• Page End: 238
• Publication Date: 2017-02-01
• Subjects: adverse effect -- drug–drug interactions -- metabolism; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12500
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Drug‐induced nephrotoxicity is potentially lethal. When sodium aescinate is given to surgical inpatients to treat postoperative inflammation and oedema, adverse drug reactions and drug–drug interactions must be closely monitored. Case description: We report a case of a 58‐year‐old man with phalangeal fractures who suffered from acute kidney injury that was most likely induced by the drug interaction between sodium aescinate and ginkgo biloba extract due to the protein‐binding and metabolic characteristics of these drugs. What is new and conclusion: Close monitoring and the prompt discontinuation of drugs that have high protein‐binding capacity and hepatic metabolism are necessary to avoid drug–drug interactions in patients who are treated with sodium aescinate. Abstract : SCr and BUN increased significantly, respectively 5.2 times and 4 times to the initial SCr and BUN parameter, in the past 2 weeks sodium aescinate(10 mg q.d.) and ginkgo biloba extract were administered. Then SCr and BUN decreased after sodium aescinate and ginkgo biloba extract were discontinued.